VIDEO: 'Significant progress' in mantle cell lymphoma leads to recent approvals
Click Here to Manage Email Alerts
In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses mantle cell lymphoma research presented at ASCO Annual Meeting.
Increasing interest in the development of new therapies for mantle cell lymphoma, such as chimeric antigen receptor T-cell therapy and bispecific antibodies, has been fueling research, Matasar said.
“There is a lot of increasing interest in developing newer therapies for mantle cell lymphoma," he said. "It really is a disease that has received a great amount of attention, with significant progress."
Matasar said t his attention has led to recent approvals of treatments including pirtobrutinib (Jaypirca, Eli Lilly & Co.) and brexucabtagene autoleucel (Tecartus, Kite Pharma/Gilead Sciences).”
Collapse
Healio interviews
Read more about
Click Here to Manage Email Alerts